Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Expenses:
Consulting (Note 11)	$ 45,000	$ 0	$ 90,000	$ 24,021
Research and development (Note 10)	283,269	295,830	912,892	575,999
Selling, general and administrative (Note 9)	116,163	113,607	310,987	319,132
Stock-based compensation (Note 7)	80,267	169,373	336,107	537,019
Total expenses	524,699	578,810	1,649,986	1,456,171
Net loss	(524,699)	(578,810)	(1,649,986)	(1,456,171)
Other comprehensive loss
Currency translation differences	(22,525)	0	(46,409)	0
Total comprehensive loss	$ (547,224)	$ (578,810)	$ (1,696,395)	$ (1,456,171)
Net loss per share - basic and diluted (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average number of common shares outstanding – basic and diluted (in shares)	91,422,569	91,422,569	91,422,569	89,476,981